# Fred Cohen

> Fred Cohen is a Series A investor at Vida Ventures backing Biotechnology and Therapeutics. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vida Ventures](https://shizune.co/investors/profile/vida-ventures)
- Location: San Francisco Bay Area, United States
- Total investments: 12
- Last investment: Jun 2026
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/fred-cohen-77688368

Fred Cohen is a Series A investor at Vida Ventures in San Francisco Bay Area focused on Biotechnology and Therapeutics. Fred Cohen - Co-Founder & Sr. Managing Director @ Vida Ventures

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Therapeutics | 5 | 42% |
| Health Care | 4 | 33% |
| Medical | 3 | 25% |
| Life Science | 2 | 17% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 25% |
| Series B | 2 | 17% |
| Series C | 2 | 17% |
| Series D | 1 | 8% |
| Series E | 1 | 8% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ollin Biosciences | Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $330M | Series B | Jun 24, 2026 |  |
| ProLynx | ProLynx is a biotechnology company that develops proprietary drug-delivery technologies designed to extend the half-life of therapeutic molecules, including peptides, proteins, and small molecules, so they maintain effective levels in the body for controlled periods. The company’s core platform uses β-eliminative linkers that are programmed torelease native drugs from macromolecular carriers (such as circulating polymers or hydrogel microspheres) at predictable rates, enabling sustained release over weeks to months. ProLynx applies this technology to create long-acting therapeutic candidates and partners with pharmaceutical firms and academic researchers to design and test novel drug conjugates. Its pipeline includes extended-duration therapies for metabolic and obesity indications, with a focus on formulations engineered for monthly or quarterly dosing schedules. | $70M | Series A | Dec 11, 2025 |  |
| Ollin Biosciences | Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $100M | Series A | Sep 17, 2025 |  |
| HI-Bio | Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases. The company's lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to deplete CD38+ cells that include plasma cells and natural killer, or NK, cells which mayallow for applications that improve clinical outcomes in a broad range of immune-mediated diseases. | $120M | Series A | Nov 01, 2022 |  |
| Kyverna Therapeutics | KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. | $85M | Series B | Jan 26, 2022 |  |
| Roka Bioscience | Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory.Rokais focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come. | $47.5M | Series D | Jan 08, 2012 |  |
| CareDx | CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products underdevelopment. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored. | $14.4M | Series G | Aug 05, 2009 |  |
| CareDx | CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products underdevelopment. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored. | $26.5M | Series E | Dec 01, 2005 |  |
| Five Prime Therapeutics | FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­callyrel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures. | $45M |  | Feb 08, 2005 |  |
| CareDx | CareDx is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products underdevelopment. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored. | $14.8M | Series C | Apr 15, 2004 |  |

10 of 12 investments shown.

## Co-investors
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 5 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 4 deals together
- [Burrill & Company](https://shizune.co/investors/profile/burrill-co) — VC Fund, 2 deals together
- [Integral Capital Partners](https://shizune.co/investors/profile/integral-capital-partners) — VC Fund, 2 deals together
- [Mubadala Capital](https://shizune.co/investors/profile/mubadala-capital) — VC Fund, 2 deals together
- [Sprout Group](https://shizune.co/investors/profile/the-sprout-group) — VC Fund, 2 deals together

## About Vida Ventures

VC Fund · Boston, United States

Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .

5 contacts available at Vida Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Fred Cohen | Co-Founder & Sr. Managing Director | https://shizune.co/investors/profile/fred-cohen |
| Helen Kim | Senior Managing Director | https://shizune.co/investors/profile/helen-s-kim-1469 |
| Mark Springel | Associate | https://shizune.co/investors/profile/mark-springel |
| Arie Belldegrun | Co-Founder & Senior Managing Director; Founding Partner | https://shizune.co/investors/profile/arie-belldegrun |
| Arjun Goyal | Co-Founder and Managing Director | https://shizune.co/investors/profile/arjun-goyal |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Fred Cohen invest in?

Fred Cohen invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fred Cohen last invest?

The most recent investment recorded for Fred Cohen closed in Jun 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co